Belite Bio (BLTE) Tax Provisions (2023 - 2024)
Belite Bio (BLTE) posted quarterly Tax Provisions of -$6.0 million for Q3 2024, down 599500.0% year-over-year from N/an in Q4 2023, and down 199.9% on a QoQ basis from $6.0 million in Q1 2024.
Belite Bio (BLTE) Tax Provisions (2023 - 2024) Analysis & Trends
Belite Bio (BLTE) has reported Tax Provisions for 2 consecutive years, with -$6.0 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Tax Provisions fell 599500.0% year-over-year to -$6.0 million; the TTM figure through Dec 2024 stood at $6000.0 (down 99.93% YoY), while the FY2024 annual figure was $6000.0, down 33.33% from the prior year.
- Tax Provisions came in at -$6.0 million for Q3 2024 at Belite Bio, down from $6.0 million in the prior quarter.
- The five-year high for Tax Provisions was $6.0 million in Q1 2023, with the low at -$6.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn | - |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - | -859,000.00 |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn | 31.86 Mn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn | 221.50 Mn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn | -459,000.00 |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn | 60.00 Mn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn | 15.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - | - |
| 10 | Belite Bio | 96.77 Mn | 96.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 6.00 Mn |